IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients
Fan, Xiao-Hong1; Geng, Jian-Zhang2; Wang, Li-Fen1; Zheng, Ying-Ying1; Lu, Hai-Ying1; Li, Jing2; Xu, Xiao-Yuan1
关键词Hepatitis B Chronic Cirrhosis Decompensated De novo combination Lamivudine Adefovir dipivoxil
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2011-11-21
DOI10.3748/wjg.v17.i43.4804
17期:43页:4804-4809
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]LIVER-DISEASE ; E-ANTIGEN ; VIRUS ; CIRRHOSIS ; RESISTANT ; SURVIVAL ; SEROCONVERSION ; CHILD ; MELD ; HBE
英文摘要

AIM: To investigate the appropriate time for combination therapy in HBeAg positive chronic hepatitis B (CHB) patients with decompensated cirrhosis.

METHODS: Thirty HBeAg positive CHB patients with decompensated cirrhosis were enrolled in the study. All of the patients were given 48 wk combination therapy with lamivudine (LAM) and adefovir dipivoxil (ADV). Briefly, 10 patients were given the de novo combination therapy with LAM and ADV, whereas the other 20 patients received ADV in addition to LAM after hepatitis B virus (HBV) genetic mutation.

RESULTS: Serum alanine aminotransferase and total bilirubin were both improved in the two groups at 4, 12, 24 and 48 wk after treatment. Serum albumin was also improved at 24 and 48 wk after combination therapy in both groups. The serum HBV DNA level was still detectable in every patient in the two groups at 4 and 12 wk after combination treatment. However, in the de novo combination group, serum HBV DNA levels in 4 (40%) and 9 (90%) patients was decreased to below 1x10(3) copies/mL at 24 and 48 wk after the combination treatment, respectively. In parallel, serum HBV DNA levels in 2 (20%) and 8 (40%) patients in the add-on combination group became undetectable at 24 and 48 wk after combination treatment, respectively. Furthermore, 6 (60%) patients in the de novo combination group achieved HBeAg seroconversion after 48 wk treatment, whereas only 4 (20%) patients in the add-on combination group achieved seroconversion. Child-Pugh score of patients in the de novo combination group was better than that of patients in the add-on combination group after 48 wk treatment. Moreover, patients in the de novo combination group had a significantly decreased serum creatinine level and elevated red blood cell counts.

CONCLUSION: De novo combination therapy with LAM and ADV was better than add-on combination therapy in terms of Child-Pugh score, virus inhibition and renal function. (C) 2011 Baishideng. All rights reserved.

语种英语
WOS记录号WOS:000298004000009
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62291
专题北京大学第一临床医学院_感染疾病科
北京大学第三临床医学院_妇产科
作者单位1.Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100034, Peoples R China
2.Shijiazhuang Fifth Hosp, Dept Infect Dis, Shijiazhuang 050021, Hebei Province, Peoples R China
推荐引用方式
GB/T 7714
Fan, Xiao-Hong,Geng, Jian-Zhang,Wang, Li-Fen,et al. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2011,17(43):4804-4809.
APA Fan, Xiao-Hong.,Geng, Jian-Zhang.,Wang, Li-Fen.,Zheng, Ying-Ying.,Lu, Hai-Ying.,...&Xu, Xiao-Yuan.(2011).De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.WORLD JOURNAL OF GASTROENTEROLOGY,17(43),4804-4809.
MLA Fan, Xiao-Hong,et al."De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients".WORLD JOURNAL OF GASTROENTEROLOGY 17.43(2011):4804-4809.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Fan, Xiao-Hong]的文章
[Geng, Jian-Zhang]的文章
[Wang, Li-Fen]的文章
百度学术
百度学术中相似的文章
[Fan, Xiao-Hong]的文章
[Geng, Jian-Zhang]的文章
[Wang, Li-Fen]的文章
必应学术
必应学术中相似的文章
[Fan, Xiao-Hong]的文章
[Geng, Jian-Zhang]的文章
[Wang, Li-Fen]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。